



## UNITED STATES \_EPARTMENT OF COMMERCE Patent and Trademark Office

Address COMMISSIONER OF PATENTS AND TRADEMARKS

SERIAL NUMBER FILING DATE	FIRST NAMED APPLICA	NT	ATTORNEY DOCKET NO.
04/6.0±740 02/06/84 c	LIVIN	· c	luv, vullere
Annex, EIRCH, MC KIE & E NE THINAS CIRCLE, N. W.	ескат П	HEUKINA	EXAMINER
RECEIVED	044±13696	ARTU	INIT PAPER NUMBER
AUG - 7 1985	044#1369¢ DOCKE <u>I</u> ED	1.1.7	5
	90	DATE MAIL	60: 09/11/91

This is a BANNERON BIRCH examiner in charge of vo. A & Bication 1985.

MCKIE CAMBESKETT OF PATENTS AND TRADEMARKS

accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

Supet. 4,1985 This application has been examined. Responsive to communication filed on \_\_\_\_\_\_ This action is mad for restriction. purposes only A shortened statutory period for response to this action is set to expire \_\_\_\_\_ month(s), \_\_\_\_\_ days from the date of this letter. \_\_\_\_\_ This action is made final. Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133 THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION: Notice of References Cited by Examiner, PTO-892.

Notice of Art Cited by Applicant, PTO-1449

Notice of Art Cited by Applicant, PTO-1449

Notice of informal Patent Application, Form PTO-152 L. 3. 5. Information on How to Effect Drawing Changes, PTO-1474 Part II SUMMARY OF ACTION 6. Claims 1- 30 are subject to restriction or election requirement. 7. 📺 This application has been filed with informal drawings which are acceptable for examination purposes until such time as allowable subject matter is indicated. 8. Allowable subject matter having been indicated, formal drawings are required in response to this Office action. 9. The corrected or substitute drawings have been received on \_\_\_\_\_\_. These drawings are 🔲 acceptable; not acceptable (see explanation). 10. The proposed drawing correction and/or the proposed additional or substitute sheet(s) of drawings, filed on \_ has (have) been \_\_\_ approved by the examiner. \_\_\_ disapproved by the examiner (see explanation). \_\_\_\_\_\_, has been \_\_\_\_ approved. \_\_\_\_ disapproved (see explanation). However, 11. The proposed drawing correction, filed\_\_\_\_\_ the Patent and Trademark Office no longer makes drawing changes. It is now applicant's responsibility to ensure that the drawings are corrected. Corrections MUST be effected in accordance with the instructions set forth on the attached letter "INFORMATION ON HOW TO EFFECT DRAWING CHANGES", PTO-1474. 12. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has \_\_\_\_ been received \_\_\_\_ not been received 🛅 been filed in parent application, serial no. 🔔 \_\_\_\_; filed on \_ 13. \_\_\_\_\_ Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in

Serial No. 670740
Art Unit 127

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10, drawn to a hybridoma and the moleclonal antibody that it produces, classified in Class 435, subclass 240.
- II. Claims 11-22, drawn to a method of producing purified stem cells, classified in Class 435, subclass 240.
- III. Claims 23-26, drawn to a purified cell product, classified in Class 435, subclass 240.
- IV. Claims 27-30, drawn to a method of medical treatment, classified in Class 424, subclass 95.

Inventions I and II are related as product and process of use.

The inventions are distinct if either (1) the process for using the product as claimed can be practiced with another and materially different product, or (2) the product as claimed can be used in a materially different process of using the product. MPEP 806.05(h).

In this case, the process as claimed can be practiced with another materially different product such as a polyvalent antisera or a different hybridoma and monoclonal antibody. Moreover, the hyrbidoma and monoclonal antibody can be used in a different process, for example, in an assay system.

Serial No. 670740

Art Unit 127

Inventions II and III are related as process of making and product made.

The inventions are distinct if either (1) the process as claimed can be used to make another and materially different product, or (2) the product as claimed can be made by another and materially different process. MPEP 806.05(f).

In this case, the product as claimed can be made by a materially different process, such as cloning and culturing a single stem cell, or by purifying a stem cell population using a polyclonal antisera.

Inventions III and IV are related as product and process of use.

The inventions are distinct if either (1) the process for using the product as claimed can be practiced with another and materially different product, or (2) the product as claimed can be used in a materially different process of using the product. MPEP 806.05(h).

In this case, the product as claimed can be used in a materially different process such as pharmaceutical testing or standardization.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement may be traversed.

Art Unit

127

A telephone call was made to Mr. Dale Hoscheit on July 22, 1985 to request an oral election to the above restriction requirement, but did not result in an election being made.

Any inquiry concerning this communication should be directed to Jean A. Heck at telephone number 703-557-3920.

A4 Heck:bjk

A/C 703

557-3920

7/29/85

THOMAS G. WISEMAN
SUPERVISORY PATENT EXAMINER
ART UNIT 127